Takeda Bulks Up In Obesity With Orexigen Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharma signs on as a marketing partner for Orexigen's Contrave ahead of a December advisory committee meeting and a Jan. 31 PDUFA date.
You may also be interested in...
New Paradigm Would Open More Avenues To Obesity Drug Approval
Assessments of obesity drugs should look at their effects in patients grouped by health status and FDA should expand the universe of secondary endpoints available to assess benefits, a group of stakeholders says.
Obesity Drug Approval Needs A New Paradigm, Stakeholder Group Says
Group convened by George Washington University School of Public Health and Health Services recommends a “patient-centered” approach to reviewing obesity drugs that includes assessing the therapies for their risks and benefits for obese individuals who are healthy, have risk factors for co-morbidities or impairments to daily feeling or functioning, or are already sick.
Qsymia Sales Reps Recruited For Experience With Metabolic Products
Vivus will benefit from downsizing at other firms, Chief Commercial Officer Mike Miller says. The company will aggressively seek formulary coverage, expects REMS to soothe payer concerns about appropriate use of the obesity product, he notes.